医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Discovery Collaboration Agreement with Bayer

2017年11月20日 PM12:22
このエントリーをはてなブックマークに追加


 

KAWASAKI, Japan

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG (“Bayer”)(ETR:BAYN). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple targets of interest selected by Bayer, and to optimize hit peptides into therapeutic peptides or small molecule products. Bayer also holds an exercisable option to negotiate for an extension of the license to peptide-drug conjugate (PDC), diagnostic, bioimaging, and agricultural use and applications. Bayer will have the right to develop and commercialize all compounds resulting from the collaboration. Under the terms of the agreement, PeptiDream would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (¥124.5 billion). In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.

[Comment from Patrick Reid, CEO of PeptiDream Inc]
“We are extremely excited to be initiating this discovery alliance with Bayer. This is one of the broadest discovery deals PeptiDream has entered into, covering peptide therapeutics and small molecule therapeutics, and options to peptide drug conjugates (PDCs), diagnostic agents, bioimaging agents, and more. This deal further exemplifies the power of our PDPS platform and the impact it is having on early drug discovery. We greatly look forward to working with Bayer to leverage both companies’ expertise and capabilities to discover and development the next generation of first-in-class and best-in-class therapeutics.”

In the past seven years, PeptiDream has established funded discovery collaborations with 17 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, and Janssen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly, Genentech, and Shionogi.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171119005082/en/

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-44-270-1270 (Kanagawa)
p-reid@peptidream.com
http://www.peptidream.com/

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 世界患者安全サミットは不必要な帝王切開の削減を目指す
  • 武田薬品がGlobal Top Employers® 2018に認定
  • Takeda Announces Its Certification in Select Group of Global Top Employers® 2018
  • 世界の組織は20秒ごとに100万ドルを無駄にしている
  • 世界各地的组织每20秒浪费100万美元